Institution
Mount Vernon Hospital
Healthcare•Northwood, United Kingdom•
About: Mount Vernon Hospital is a healthcare organization based out in Northwood, United Kingdom. It is known for research contribution in the topics: Radiation therapy & Population. The organization has 1856 authors who have published 3044 publications receiving 148302 citations. The organization is also known as: North London Hospital for Consumption and Diseases of the Chest & Mt Vernon Hospital.
Topics: Radiation therapy, Population, Radical, Cancer, Misonidazole
Papers published on a yearly basis
Papers
More filters
••
TL;DR: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Abstract: Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of tras tuz u mab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker. Methods We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with tras tuz u mab and a taxane, to T-DM1 or la pa ti nib plus cap e ci ta bine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted. Results Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with la pa ti nib plus cap e ci ta bine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim analysis crossed the stopping boundary for efficacy (30.9 months vs. 25.1 months; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001). The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with la pa ti nib plus cap e ci ta bine; P<0.001); results for all additional secondary end points favored T-DM1. Rates of adverse events of grade 3 or above were higher with la pati nib plus cap e ci ta bine than with T-DM1 (57% vs. 41%). The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar–plantar erythro dysesthesia were higher with la pa ti nib plus cap e ci ta bine. Conclusions T-DM1 significantly prolonged progression-free and overall survival with less toxicity than la pa ti nib plus cap e ci ta bine in patients with HER2-positive advanced breast cancer previously treated with tras tuz u mab and a taxane. (Funded by F. Hoffmann– La Roche/Genentech; EMILIA ClinicalTrials.gov number, NCT00829166.)
2,862 citations
••
National Health Service1, University of Oslo2, Karolinska Institutet3, University of Bergen4, Queen's University Belfast5, Curie Institute6, Umeå University7, Mount Vernon Hospital8, Leeds Teaching Hospitals NHS Trust9, Cancer Research UK10, Norwegian University of Science and Technology11, Comenius University in Bratislava12, University of São Paulo13, Algeta14, Bayer Corporation15, Tulane University16
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Abstract: efit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. Conclusions In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Phar -
2,614 citations
••
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Abstract: Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. Methods In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy. The primary end point was overall survival. Results At the preplanned interim overall survival analysis, which was performed after 77% of the total number of expected events occurred, the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005). The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014. Median progression-free survival was 11.4 months in the combinationtherapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). The objective response rate was 64% in the combinationtherapy group and 51% in the vemurafenib group (P<0.001). Rates of severe adverse events and study-drug discontinuations were similar in the two groups. Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group. Conclusions Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.)
2,144 citations
••
Memorial Sloan Kettering Cancer Center1, Baylor University Medical Center2, Northwestern University3, University of Manchester4, Peking University5, Mount Vernon Hospital6, Ludwig Maximilian University of Munich7, University of Sydney8, University of Miami9, University College London10, University of Glasgow11, Kindai University12, Karolinska Institutet13, Peking Union Medical College14, GlaxoSmithKline15, Harvard University16
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Abstract: Background Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy. Methods We randomly assigned 1110 patients with clear-cell, metastatic renal-cell carcinoma, in a 1:1 ratio, to receive a continuous dose of pazopanib (800 mg once daily; 557 patients) or sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment; 553 patients). The primary end point was progression-free survival as assessed by independent review, and the study was powered to show the noninferiority of pazopanib versus sunitinib. Secondary end points included overall survival, safety, and quality of life. Results Pazopanib was noninferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any caus...
1,598 citations
••
University of Warwick1, University Hospitals Birmingham NHS Foundation Trust2, University of Salford3, Cardiff University4, Institute of Cancer Research5, Beatson West of Scotland Cancer Centre6, Leeds Teaching Hospitals NHS Trust7, Weston Park Hospital8, Maidstone Hospital9, Royal Bournemouth Hospital10, Derby Hospitals NHS Foundation Trust11, Guy's Hospital12, Cheltenham General Hospital13, Queen Alexandra Hospital14, The Queen's Medical Center15, Musgrove Park Hospital16, Hull and East Yorkshire Hospitals NHS Trust17, Mount Vernon Hospital18, Royal Surrey County Hospital19, East Sussex County Council20, Western General Hospital21, Queen's University Belfast22, East Lancashire Hospitals NHS Trust23, Churchill Hospital24, Telford25, Royal Devon and Exeter Hospital26, Nottingham University Hospitals NHS Trust27, Clatterbridge Cancer Centre NHS Foundation Trust28, Swansea University29
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
1,502 citations
Authors
Showing all 1857 results
Name | H-index | Papers | Citations |
---|---|---|---|
Cyrus Cooper | 204 | 1869 | 206782 |
Richard S. Houlston | 110 | 768 | 50101 |
Erminia Calabrese | 105 | 287 | 82143 |
Philippe Lambin | 100 | 785 | 45034 |
Søren M. Bentzen | 94 | 537 | 32702 |
George R. Pettit | 89 | 848 | 31759 |
G. Wilkinson | 89 | 1016 | 35424 |
George S. Wilson | 88 | 716 | 33034 |
D. R. Johnson | 86 | 822 | 32935 |
C. Thomas | 86 | 559 | 30609 |
Chris Hays | 84 | 432 | 36593 |
A. Contu | 83 | 739 | 30387 |
Thomas Powles | 82 | 655 | 39271 |
Anwar R. Padhani | 82 | 342 | 24783 |
Peter Hoskin | 82 | 585 | 29453 |